| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.2 | 12.5 |
| Gross profit | 4.3 | 4.0 |
| Profit before tax | -1.3 | -1.6 |
| Net income | -1.4 | -1.6 |
| EPS (diluted, $ a share) | $-0.08 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -18.6% |
|---|---|
| Gross margin | 42.4% |
| Operating margin | -11.5% |
10-Q filed with the SEC, NASDAQ: IRIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Iridex Corp: key numbers
- Share price
- $0.6996Close, Nov 17
- Market cap
- $12.5M
- Shares outstanding
- 17.81MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iridex Corp
All →Iridex Financial Results
Iridex Corporation reported third quarter 2026 revenue of $10.2 million, a 19% decline year-over-year primarily due to weaker international demand and regulatory challenges. Despite the revenue drop, gross margins improved significantly to 42.4% as the company executes a strategic review and cost-reduction plan, including a headquarters relocation.
- Term
- Q3 2026
“On the top line, revenue came in below our expectations this quarter, driven by weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges. At the same time, we continue to experience the benefits from the cost savings programs initiated when I was named CEO, including the recent relocation of our headquarters.”
Patrick Mercer, President and CEO of Iridex
“We are now deep into a strategic review of our product lines, and as part of that work we are reprioritizing our resources toward our most profitable opportunities. With this focus, we expect to enter 2027 with better margins, a lower cost base, and a business model better aligned toward cash flow generation.”
Patrick Mercer, President and CEO of Iridex
Iridex Insider Shih-Yao David Lin Buys $380K of Stock
Shih-Yao David Lin bought 298,347 shares of Iridex Corp at $0.935 to $1.48 a share (average $1.28) in 14 transactions, worth $380K in total between Dec 9, 2025 and Mar 23, 2026. Shares held after the trade: 938,929 (+1.5%).
- Value
- $380K
- Shares
- 298,347
- Average price
- $1.28
- Holding change
- +1.5%
- Trade date
- Dec 9, 2025 to Mar 23, 2026
Iridex Insider Shih-Yao David Lin Buys $241K of Stock
Shih-Yao David Lin bought 233,254 shares of Iridex Corp at $0.8781 to $1.52 a share (average $1.03) in 12 transactions, worth $241K in total between Jun 6, 2025 and Dec 1, 2025. Shares held after the trade: 675,667 (+8.0%).
- Value
- $241K
- Shares
- 233,254
- Average price
- $1.03
- Holding change
- +8.0%
- Trade date
- Jun 6, 2025 to Dec 1, 2025
Iridex Insider Shih-Yao David Lin Buys $527K of Stock
Shih-Yao David Lin bought 496,931 shares of Iridex Corp at $0.8899 to $1.20 a share (average $1.06) in 14 transactions, worth $527K in total between Apr 4, 2025 and Jun 5, 2025. Shares held after the trade: 70,397 (+39.7%).
- Value
- $527K
- Shares
- 496,931
- Average price
- $1.06
- Holding change
- +39.7%
- Trade date
- Apr 4, 2025 to Jun 5, 2025